Erratum to: Impact of breast cancer on anti-mullerian hormone levels in young women

H. I. Su · S. W. Flatt · L. Natarajan ·
A. DeMichele · A. Z. Steiner

Published online: 28 March 2013
© Springer Science+Business Media New York 2013

**Erratum to: Breast Cancer Res Treat (2013)
137:571–577
DOI 10.1007/s10549-012-2361-5**

Unfortunately in the original publication of the article, author has included the standard deviations for anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH) and inhibin B (inhB) in Table 1. As confidence intervals (CI) are more interpretable for log-transformed data, the correct 95 % CI for each of these three hormones have been given below.

Table 1 Hormone measures of ovarian reserve (geometric mean [95 % CI]) of breast cancer and healthy participants

	Breast cancer participants (<i>N</i> = 108)	Healthy participants (<i>N</i> = 99)	<i>p</i> value
AMH (ng/ml)	0.66 (0.48–0.78)	1.1 (0.89–1.38)	<0.001 ^a
FSH (mIU/ml) ^b	7.7 (6.0–10.3)	7.3 (6.7–7.9)	0.52 ^a
InhB (pg/ml) ^b	27.7 (19.7–38.9)	30.9 (27.3–35.5)	0.45 ^a

^a Student's *t* test on log-transformed levels

^b Restricted to participants with estradiol levels <80 pg/ml (45 breast cancer and 91 healthy participants)

The online version of the original article can be found under doi:[10.1007/s10549-012-2361-5](https://doi.org/10.1007/s10549-012-2361-5).

H. I. Su (✉) · S. W. Flatt · L. Natarajan
Division of Reproductive Endocrinology and Infertility
and Moores UCSD Cancer Center, University
of California San Diego, 3855 Health Sciences Drive #0901,
La Jolla, CA 92093-0901, USA
e-mail: hisu@ucsd.edu

A. DeMichele
Center of Clinical Epidemiology and Biostatistics and Abramson
Cancer Center, University of Pennsylvania, 3 West Pavilion,
3400 Civic Center Boulevard, Philadelphia, PA 19104, USA

A. Z. Steiner
Division of Reproductive Endocrinology and Infertility,
University of North Carolina Chapel Hill, 4001 Old Clinic
Building, Campus Box 7570, Chapel Hill, NC 27599, USA